USP1 focuses on suppressing K11‐linked polyubiquitination of TAZ, linked to the progression of HCC, while USP19 targets K48‐ and K11‐linked chains on YAP, maintaining its activity in cancer.115, 116. Here, YAP1 is linked to hepatocellular carcinoma.